Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA
LATHAM, N.Y., July 14, 2026--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2026, which ended May 31, 2026.
Fiscal Year 2026 Fourth Quarter Financial Highlights | ||||
Quarter Ended May 31, 2026 | Pro Forma* YoY Growth | |||
Pro Forma* Net Sales | $86.6 million | 8.0% | ||
Med Tech Net Sales | $41.8 million | 16.7% | ||
Med Device Net Sales | $44.8 million | 1.1% |
GAAP gross margin of 54.0%
GAAP loss per share of $0.27
Adjusted loss per share of $0.07
Adjusted EBITDA of $3.3 million
Fiscal Year 2026 Financial Highlights | ||||
Year Ended May 31, 2026 | Pro Forma* YoY Growth | |||
Pro Forma* Net Sales | $320.2 million | 9.4% | ||
Med Tech Net Sales | $150.0 million | 18.4% | ||
Med Device Net Sales | $170.2 million | 2.5% |
GAAP gross margin of 54.6%
GAAP loss per share of $0.88
Adjusted loss per share of $0.24
Adjusted EBITDA of $13.2 million
Ended fiscal year 2026 with $53.9 million in cash
*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued RadioFrequency and Syntrax products in February 2024.
Clinical, Regulatory, and Market Access Highlights
During the fiscal year:
Received FDA IDE approval for APEX-Return study evaluating AlphaReturn Blood Management System when used with AlphaVac F1885 System
Received FDA IDE approval for PAVE clinical study evaluating AngioVac System for treatment of right-sided infective endocarditis
Initiated both the AMBITION BTK and RECOVER-AV trials
During the fourth quarter:
Two-year follow up data from its PRESERVE pivotal trial presented at the American Urological Association conference in 2026 demonstrating NanoKnife's durable prostate cancer outcomes
Palmetto GBA (Government Benefits Administrators) finalized a local coverage determination covering NanoKnife IRE for qualifying Medicare patients in prostate and liver cancer, effective July 5, 2026
Subsequent to fiscal year end:
Received FDA IDE (Investigational Device Exemption) approval for the RELIEF study evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia
"Our strong fourth quarter capped a year of consistent execution at AngioDynamics," said Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Full-year Med Tech growth of more than 18% reflects the continued progress of our strategic transformation, as our innovative platform technologies across cardiology and interventional oncology took share in large, fast-growing global markets. Combined with our operational discipline, that growth drove continued profitability even as we absorbed tariff-related headwinds."